
Quarterly report 2022-Q3
added 11-10-2022
Viveve Medical Revenue 2011-2026 | VIVE
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Viveve Medical
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 6.43 M | 5.48 M | 6.57 M | 18.5 M | 15.3 M | 7.14 M | 1.45 M | 90 K | 1.27 M | 1.08 M | 671 K |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 18.5 M | 90 K | 5.82 M |
Quarterly Revenue Viveve Medical
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 1.68 M | 1.8 M | 1.64 M | - | 1.62 M | 1.65 M | 1.45 M | - | 1.52 M | 704 K | 1.3 M | - | 1.05 M | 1.05 M | 3.01 M | - | 4.82 M | 5.52 M | 3.7 M | - | 4.07 M | 3.08 M | 3.04 M | - | 1.85 M | 1.56 M | 1.28 M | - | 584 K | 73 K | 38 K | - | 17 K | 73 K | 47 K | - | 4.61 K | 372 K | 348 K | - | 212 K | 363 K | 20 K | - | 27 K | 398 K | 57 K |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 5.52 M | 4.61 K | 1.39 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Medical devices industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
GenMark Diagnostics, Inc.
GNMK
|
172 M | - | - | $ 1.77 B | ||
|
Allied Healthcare Products
AHPI
|
6.02 M | - | 3.58 % | $ 2.21 M | ||
|
Obalon Therapeutics, Inc.
OBLN
|
1.59 M | - | -5.86 % | $ 30.6 M | ||
|
Apollo Endosurgery
APEN
|
76.9 M | - | - | $ 475 M | ||
|
Alphatec Holdings
ATEC
|
764 M | $ 7.73 | 10.52 % | $ 1.16 B | ||
|
EDAP TMS S.A.
EDAP
|
44.1 M | $ 4.15 | 15.44 % | $ 155 M | ||
|
Aziyo Biologics
AZYO
|
12.3 M | - | 1.37 % | $ 20.5 M | ||
|
Avinger
AVGR
|
7.65 M | - | -20.74 % | $ 369 K | ||
|
Axonics Modulation Technologies
AXNX
|
274 M | - | - | $ 3.31 B | ||
|
Helius Medical Technologies
HSDT
|
644 K | $ 2.17 | -2.25 % | $ 1.32 M | ||
|
BioSig Technologies
BSGM
|
40 K | - | 37.08 % | $ 85.7 M | ||
|
BIOLASE
BIOL
|
49.2 M | - | -13.19 % | $ 166 K | ||
|
Conformis
CFMS
|
62 M | - | - | $ 16.4 M | ||
|
OrthoPediatrics Corp.
KIDS
|
236 M | $ 17.41 | 1.69 % | $ 408 M | ||
|
ClearPoint Neuro
CLPT
|
37 M | $ 11.6 | 1.13 % | $ 328 M | ||
|
Cardiovascular Systems
CSII
|
236 M | - | 0.15 % | $ 844 M | ||
|
LENSAR
LNSR
|
58.4 M | $ 5.37 | -0.37 % | $ 64.2 M | ||
|
CryoLife, Inc.
CRY
|
253 M | - | -4.14 % | $ 702 M | ||
|
Cytosorbents Corporation
CTSO
|
37.1 M | $ 0.61 | 6.93 % | $ 38 M | ||
|
LivaNova PLC
LIVN
|
1.39 B | $ 70.6 | 6.55 % | $ 3.85 B | ||
|
Delcath Systems
DCTH
|
85.2 M | $ 11.22 | -0.36 % | $ 402 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
4.25 K | - | -1.98 % | $ 98.3 M | ||
|
Itamar Medical Ltd.
ITMR
|
41 M | - | 0.03 % | $ 1.58 B | ||
|
Misonix, Inc.
MSON
|
62.5 M | - | - | $ 462 M | ||
|
Neovasc
NVCN
|
2.55 M | - | - | $ 111 M | ||
|
IRIDEX Corporation
IRIX
|
52.7 M | $ 1.04 | - | $ 17.6 M | ||
|
Dynatronics Corporation
DYNT
|
27.4 M | - | 14.99 % | $ 929 K | ||
|
Eargo
EAR
|
37.2 M | - | - | $ 10.2 M | ||
|
Myomo
MYO
|
40.9 M | $ 0.86 | 1.36 % | $ 36 M | ||
|
Electromed
ELMD
|
64 M | $ 26.63 | 2.58 % | $ 225 M | ||
|
Orthofix Medical
OFIX
|
822 M | $ 12.25 | 0.49 % | $ 485 M | ||
|
Butterfly Network
BFLY
|
82.1 M | $ 4.27 | -6.05 % | $ 904 M | ||
|
Intersect ENT, Inc.
XENT
|
80.6 M | - | - | $ 955 M | ||
|
Second Sight Medical Products
EYES
|
1 K | - | -0.97 % | $ 54.4 M | ||
|
Insulet Corporation
PODD
|
2.71 B | $ 161.82 | 6.97 % | $ 11.4 B | ||
|
GBS
GBS
|
3.05 M | - | -0.57 % | $ 7.12 M | ||
|
Globus Medical
GMED
|
2.94 B | $ 86.9 | -2.59 % | $ 11.8 B | ||
|
Sintx Technologies
SINT
|
1.02 M | $ 2.41 | 0.42 % | $ 6.68 M | ||
|
CONMED Corporation
CNMD
|
1.37 B | $ 38.02 | 1.77 % | $ 1.18 B | ||
|
Inspire Medical Systems
INSP
|
912 M | $ 46.04 | 0.59 % | $ 1.35 B | ||
|
Integer Holdings Corporation
ITGR
|
1.85 B | $ 87.96 | 1.95 % | $ 3.06 B | ||
|
Invacare Corporation
IVC
|
181 M | - | - | $ 24.7 M | ||
|
Stryker Corporation
SYK
|
7.17 B | $ 296.12 | 1.32 % | $ 113 B | ||
|
Edwards Lifesciences Corporation
EW
|
6.07 B | $ 83.32 | 0.16 % | $ 48.7 B | ||
|
Tandem Diabetes Care
TNDM
|
290 M | $ 18.59 | 3.11 % | $ 1.26 B | ||
|
Tactile Systems Technology
TCMD
|
330 M | $ 26.4 | 4.35 % | $ 604 M | ||
|
TransMedics Group
TMDX
|
605 M | $ 72.87 | -0.07 % | $ 2.48 B |